DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer

Information source: Sun Yat-sen University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Capecitabine (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Sun Yat-sen University

Official(s) and/or principal investigator(s):
Yuan Zhong-yu, MD, Study Director, Affiliation: Sun Yat-sen University

Overall contact:
Yuan Zhong-yu, MD, Phone: 86-20-87343347, Email: yuanzhygz@163.com

Summary

The primary objective of this study is to compare disease-free survival (DFS) of patients with triple negative breast cancer randomised to treatment with standard adjuvant chemotherapy alone or to standard adjuvant chemotherapy followed by 1 year of Capecitabine (Xeloda) metronomic therapy.

Clinical Details

Official title: Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: disease-free survival

Detailed description: Triple negative breast cancer (TNBC) is an aggressive disease without tumor-specific treatment options. Patients with triple-negative disease had an increased likelihood of distant recurrence and death within 5 years of diagnosis. Median time to distant recurrence was significantly shorter. This study will evaluate the efficacy and safety of the addition of Capecitabine (Xeloda) to standard adjuvant therapy in patients with triple negative breast cancer. Patients will be randomized to receive either standard chemotherapy (according to NCCN guideline), or standard chemotherapy followed by 1 year of metronomic Capecitabine (650mg/m2, twice every day). The anticipated time on study treatment is 6-12 months, and the target sample size is 424 individuals. Disease-free Survival (DFS) will be primary end point.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Patients must be >=18 years of age;

- The patients must be Operable primary invasive breast cancer;

- Definitive loco-regional surgery must be completed;

- Primary tumor centrally confirmed as triple negative;

- Operable node-positive (or node-negative with tumor diameter ≥ 0. 5cm);

- Chest, abdominal, bone imaging performed with 3 months prior to randomization must

not reveal the presence of distant spread;

- There are normal organ function, including bone marrow function, renal function,

liver function, and cardiac function;

- All patients must have signed and dated an informed consent form.

Exclusion Criteria:

- Patients with bilateral breast cancer, inflammatory carcinomas;

- Patients with positive supraclavicular or internal mammary lymph node;

- Previous breast cancer history;

- Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of

the skin, or basal cell carcinoma of the skin;

- Pregnant or breast-feeding women;

- Women who are unwilling to agree to use an effective non-hormonal method of

contraception during the treatment period of Xeloda;

- Any sex hormonal therapy;

- Malabsorption syndrome.

Locations and Contacts

Yuan Zhong-yu, MD, Phone: 86-20-87343347, Email: yuanzhygz@163.com

Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong 510060, China; Recruiting
Yuan Zhong-yu, MD, Phone: 86-20-87343347, Email: yuanzhygz@163.com
Wang Xi, MD, Phone: 86-20-62354672, Email: wangxi@sysucc.org.cn
Yuan Zhong-yu, MD, Sub-Investigator
Additional Information

Starting date: April 2010
Last updated: February 12, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017